What is HC Wainwright’s Forecast for DMAC Q1 Earnings?

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) – Research analysts at HC Wainwright upped their Q1 2026 earnings per share estimates for DiaMedica Therapeutics in a note issued to investors on Wednesday, April 1st. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($0.17) per share for the quarter, up from their previous estimate of ($0.18). The consensus estimate for DiaMedica Therapeutics’ current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for DiaMedica Therapeutics’ Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.75) EPS and FY2028 earnings at ($0.35) EPS.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.17) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.17). The company had revenue of ($0.03) million for the quarter, compared to analysts’ expectations of $13.50 million.

DMAC has been the topic of a number of other reports. Lake Street Capital reissued a “buy” rating on shares of DiaMedica Therapeutics in a report on Monday, January 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $12.33.

DiaMedica Therapeutics Price Performance

DMAC stock opened at $6.48 on Friday. The firm has a market capitalization of $349.14 million, a PE ratio of -9.26 and a beta of 1.16. DiaMedica Therapeutics has a twelve month low of $3.19 and a twelve month high of $10.42. The stock has a 50-day simple moving average of $7.76 and a two-hundred day simple moving average of $7.63.

Hedge Funds Weigh In On DiaMedica Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cooperman Leon G raised its holdings in shares of DiaMedica Therapeutics by 98.2% in the 3rd quarter. Cooperman Leon G now owns 3,269,761 shares of the company’s stock valued at $22,463,000 after acquiring an additional 1,619,761 shares in the last quarter. Millennium Management LLC purchased a new position in shares of DiaMedica Therapeutics during the third quarter worth about $8,157,000. Geode Capital Management LLC grew its holdings in shares of DiaMedica Therapeutics by 99.6% during the second quarter. Geode Capital Management LLC now owns 630,148 shares of the company’s stock worth $2,458,000 after purchasing an additional 314,407 shares in the last quarter. Paragon Associates & Paragon Associates II Joint Venture increased its position in shares of DiaMedica Therapeutics by 34.6% in the third quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 875,000 shares of the company’s stock worth $6,011,000 after purchasing an additional 225,000 shares during the last quarter. Finally, Royal Bank of Canada increased its position in shares of DiaMedica Therapeutics by 46,879.1% in the first quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock worth $588,000 after purchasing an additional 154,701 shares during the last quarter. 10.12% of the stock is currently owned by hedge funds and other institutional investors.

DiaMedica Therapeutics News Roundup

Here are the key news stories impacting DiaMedica Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its Q1 2026 EPS forecast to ($0.17) from ($0.18), signaling slightly smaller expected losses for the quarter. MarketBeat Report
• Positive Sentiment: Q2 2026 EPS estimate was lifted to ($0.18) from ($0.19), another incremental improvement to near‑term profitability expectations. MarketBeat Report
• Positive Sentiment: Q3 2026 EPS now projected at ($0.19), up from ($0.20), continuing the trend of reduced loss estimates across 2026 quarters. MarketBeat Report
• Positive Sentiment: Q4 2026 EPS was raised to ($0.21) from ($0.22), consistent with HC Wainwright nudging 2026 quarterly forecasts toward smaller losses. MarketBeat Report
• Positive Sentiment: HC Wainwright lifted FY2026 and FY2027 EPS estimates to ($0.75) from ($0.79), trimming expected full‑year losses and implying improving operating outlook vs. prior forecasts. MarketBeat Report
• Positive Sentiment: FY2028 EPS was nudged to ($0.35) from ($0.37), another minor upgrade in the multi‑year outlook. MarketBeat Report
• Positive Sentiment: HC Wainwright published a long‑range estimate projecting FY2030 EPS of $0.56, marking an expected transition to profitability in their model — a materially positive long‑term signal if the company hits the pathway to that outcome. MarketBeat Report
• Negative Sentiment: HC Wainwright slightly lowered its FY2029 EPS view to $0.14 from $0.15 — a small downgrade that partially offsets the otherwise uniform set of upgrades. MarketBeat Report

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.